CARLO STELLA, CARMELO
CARLO STELLA, CARMELO
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale
Methodological framework for radiomics applications in Hodgkin’s lymphoma
2020 M. Sollini, M. Kirienko, L. Cavinato, F. Ricci, M. Biroli, F. Ieva, L. Calderoni, E. Tabacchi, C. Nanni, P. Luigi Zinzani, S. Fanti, A. Guidetti, A. Alessi, P. Corradini, E. Seregni, C. Carlo Stella, A. Chiti
FGF trapping inhibits multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress
2020 R. Ronca, G.C. Ghedini, F. Maccarinelli, A. Sacco, S.L. Locatelli, E. Foglio, S. Taranto, E. Grillo, S. Matarazzo, R. Castelli, G. Paganini, V. Desantis, N. Cattane, A. Cattaneo, M. Mor, C. Carlo-Stella, A. Belotti, A. Roccaro, M. Presta, A. Giacomini
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide
2019 J. Mariotti, D. Taurino, F. Marino, S. Bramanti, B. Sarina, L. Morabito, C. De Philippis, C. Di Vito, D. Mavilio, C. Carlo-Stella, M. Della Porta, A. Santoro, L. Castagna
Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma
2018 V. Spina, A. Bruscaggin, A. Cuccaro, M. Martini, M. Di Trani, G. Forestieri, M. Manzoni, A. Condoluci, A. Arribas, L. Terzi-Di-Bergamo, S.L. Locatelli, E. Cupelli, L. Ceriani, A.A. Moccia, A. Stathis, L. Nassi, C. Deambrogi, F. Diop, F. Guidetti, A. Cocomazzi, S. Annunziata, V. Rufini, A. Giordano, A. Neri, R. Boldorini, B. Gerber, F. Bertoni, M. Ghielmini, G. Stüssi, A. Santoro, F. Cavalli, E. Zucca, L.M. Larocca, G. Gaidano, S. Hohaus, C. Carlo-Stella, D. Rossi
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
2017 S. Trabanelli, M.F. Chevalier, A. Martinez Usatorre, A. Gomez Cadena, B. Salomã©, M. Lecciso, V. Salvestrini, G. Verdeil, J. Racle, C. Papayannidis, H. Morita, I. Pizzitola, C. Grandclã©ment, P. Bohner, E. Bruni, M. Girotra, R. Pallavi, P. Falvo, E.O. Leibundgut, G.M. Baerlocher, C. Carlo-Stella, D. Taurino, A. Santoro, O. Spinelli, A. Rambaldi, E. Giarin, G. Basso, C. Tresoldi, F. Ciceri, D. Gfeller, C.A. Akdis, L. Mazzarella, S. Minucci, P.G. Pelicci, E. Marcenaro, A.N..J. Mckenzie, D. Vanhecke, G. Coukos, D. Mavilio, A. Curti, L. Derrã©, C. Jandus
Italian real life experience with brentuximab vedotin : results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma
2017 A. Broccoli, C. Pellegrini, A. Di Rocco, B. Puccini, C. Patti, G. Gini, D. Mannina, M. Tani, C..M. Rusconi, A. Romano, A. Vanazzi, B. Botto, C. Carlo Stella, S. Hohaus, P. Musto, P. Mazza, S. Molica, P. Corradini, A. Fama, F. Gaudio, M. Merli, A. Gravetti, G. Gritti, A. Arcari, P. Tosi, A.M. Liberati, A. Pinto, V. Pavone, F. Gherlinzoni, V. Naso, S. Volpetti, L. Trentin, M.C. Goldaniga, M. Bonfichi, A. De Renzo, C. Schiavotto, M. Spina, S. Storti, A.M. Carella, V. Stefoni, L. Argnani, P.L. Zinzani
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest
2016 S.L. Locatelli, G. Careddu, G. Inghirami, L. Castagna, P. Sportelli, S. Santoro, C. Carlo Stella
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation
2016 S. Bramanti, A. Nocco, E. Mauro, G. Milone, L. Morabito, B. Sarina, R. Crocchiolo, I. Timofeeva, R. Capizzuto, C. Carlo Stella, A. Santoro, L. Castagna
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes
2016 R. Devillier, S. Bramanti, S. Fürst, B. Sarina, J. El Cheikh, R. Crocchiolo, A. Granata, C. Chabannon, L. Morabito, S. Harbi, C. Faucher, A. Santoro, P..J. Weiller, N. Vey, C. Carlo-Stella, L. Castagna, D. Blaise
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide
2016 L. Castagna, S. Bramanti, S. Furst, L. Giordano, B. Sarina, R. Crocchiolo, J. El Cheikh, A. Granata, L. Morabito, E. Mauro, C. Faucher, B. Mohty, S. Harbi, R. Devillier, C. Chabannon, C. Carlo Stella, A. Santoro, D. Blaise
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation
2016 L. Castagna, B. Sarina, R. Crocchiolo, S. Bramanti, S. Furst, R. Devillier, D. Coso, R. Bouabdallah, D. Mokart, L. Morabito, S. Harbi, L. Giordano, A. Rimondo, P.J. Weiller, C. Carlo-Stella, A. Santoro, C. Chabannon, D. Blaise
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study
2016 A. Santoro, R. Mazza, A. Pulsoni, A. Re, M. Bonfichi, V.R. Zilioli, F. Salvi, F. Merli, A. Anastasia, S. Luminari, G. Annechini, M. Gotti, A. Peli, A.M. Liberati, N. Di Renzo, L. Castagna, L. Giordano, C. Carlo Stella
The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide
2016 R. Crocchiolo, L. Castagna, S. Furst, R. Devillier, B. Sarina, S. Bramanti, J. El Cheikh, A. Granata, S. Harbi, L. Morabito, C. Faucher, A. Rimondo, D. Girardi, B. Mohty, B. Calmels, C. Carlo-Stella, C. Chabannon, R. Bouabdallah, A. Santoro, N. Vey, P.J. Weiller, D. Blaise
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation
2016 S.L. Locatelli, G. Careddu, G.G. Stirparo, L. Castagna, A. Santoro, C. Carlo Stella
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation
2015 M. Pennati, S. Sbarra, M. De Cesare, A. Lopergolo, S.L. Locatelli, E. Campi, M.G. Daidone, C. Carlo-Stella, A.M. Gianni, N. Zaffaroni
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant
2015 L. Castagna, R. Crocchiolo, L. Giordano, S. Bramanti, C. Carlo-Stella, B. Sarina, A. Chiti, E. Mauro, S. Gandolfi, E. Todisco, E. Balzarotti, A. Anastasia, M. Magagnoli, E. Brusamolino, A. Santoro
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment
2015 A. Carbone, A. Gloghini, L. Castagna, A. Santoro, C. Carlo-Stella
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors : mature results of an Italian randomized phase II study
2015 A. Necchi, L. Mariani, M. Di Nicola, S. Lo Vullo, N. Nicolai, P. Giannatempo, D. Raggi, E. Farè, M. Magni, L. Piva, P. Matteucci, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, C. Bengala, C. Barone, I. Schiavetto, S. Siena, C. CARLO STELLA, G. Pizzocaro, R. Salvioni, A.M. Gianni
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma
2015 L. Castagna, C. Carlo-Stella, R. Mazza, A. Santoro
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers
2015 C. Carlo-Stella, F. Ricci, S.E. Dalto, R. Mazza, M. Malagola, F. Patriarca, S. Viviani, D. Russo, L. Giordano, L. Castagna, P. Corradini, A. Santoro